AMRN – Amarin Corp ADR

AMRN — Price & Float Short

—— Fair value ★ EPS beat ★ EPS miss —— Target Price

Float Short %

2.45

Margin Of Safety %

-25

Put/Call OI Ratio

0.5

EPS Next Q Diff

0.06

EPS Last/This Y

1.73

EPS This/Next Y

0.01

Price

14.31

Target Price

Analyst Recom

Performance Q

-3.23

Upside

-299.2%

Beta

0.77

Ticker: AMRN

19 items of 1

Date	Symbol	Latest	P/C OI	P/C Vol	Total OI
2026-07-13	AMRN	14.66	0.41	4.65	3062
2026-07-14	AMRN	14.38	0.46	0.88	3195
2026-07-15	AMRN	14.46	0.46	2.52	3213
2026-07-16	AMRN	14.16	0.50	0.88	3365
2026-07-17	AMRN	13.98	0.50	0.68	3375
2026-07-20	AMRN	13.59	0.57	0.20	2504
2026-07-21	AMRN	13.95	0.53	0.07	2711
2026-07-22	AMRN	13.74	0.51	0.15	2798
2026-07-23	AMRN	13.64	0.50	0.00	2839
2026-07-24	AMRN	13.57	0.50	0.00	2857
2026-07-27	AMRN	13.81	0.50	0.09	2857
2026-07-28	AMRN	13.96	0.49	0.64	2885
2026-07-29	AMRN	14.26	0.49	0.63	2904
2026-07-30	AMRN	14.17	0.49	1.45	2950
2026-07-31	AMRN	14.26	0.49	19.67	2995
2026-08-03	AMRN	14.13	0.49	0.32	2997
2026-08-04	AMRN	14.72	0.49	0.16	3076
2026-08-05	AMRN	14.46	0.49	2.60	3110
2026-08-07	AMRN	14.29	0.50	0.50	3158
Date	Symbol	Latest	P/C OI	P/C Vol	Total OI

19 items 1 of 1

20 items of 1

Date	Ticker	Price	Current Quarter Growth Estimate	EBIT Estimation	Average EPS Estimate Current Year
2026-07-13	AMRN	14.65	-	-	-0.03
2026-07-14	AMRN	14.39	-	-	-0.03
2026-07-15	AMRN	14.49	-	-	-0.03
2026-07-16	AMRN	14.19	-	-	-0.03
2026-07-17	AMRN	14.00	-	-	-0.03
2026-07-20	AMRN	13.61	-	-	-0.03
2026-07-21	AMRN	13.89	-	-	-0.03
2026-07-22	AMRN	13.80	-	-	-0.03
2026-07-23	AMRN	13.59	-	-	-0.03
2026-07-24	AMRN	13.53	-	-	-0.03
2026-07-27	AMRN	13.78	-	-	-0.03
2026-07-28	AMRN	13.98	-	-	-0.03
2026-07-29	AMRN	14.24	-	-	-0.03
2026-07-30	AMRN	14.20	-	-	-0.03
2026-07-31	AMRN	14.27	-	-	-0.03
2026-08-03	AMRN	14.10	-	-	-0.03
2026-08-04	AMRN	14.10	-	-	-0.03
2026-08-05	AMRN	14.45	-	-	-0.03
2026-08-06	AMRN	14.32	-	-	-0.03
2026-08-07	AMRN	14.31	-	-	-0.07
Date	Ticker	Price	Current Quarter Growth Estimate	EBIT Estimation	Average EPS Estimate Current Year

20 items 1 of 1

20 items of 1

Date	Ticker	Insider Transactions	Institutional Transactions	Float Short
2026-07-13	AMRN	0.00	0.35	2.60
2026-07-14	AMRN	0.00	0.35	2.60
2026-07-15	AMRN	0.00	0.35	2.60
2026-07-16	AMRN	0.00	0.35	2.60
2026-07-17	AMRN	0.00	0.35	2.60
2026-07-20	AMRN	0.00	0.36	2.60
2026-07-21	AMRN	0.00	0.36	2.60
2026-07-22	AMRN	0.00	0.36	2.60
2026-07-23	AMRN	0.00	0.36	2.60
2026-07-24	AMRN	0.00	0.36	2.60
2026-07-27	AMRN	0.00	0.32	2.46
2026-07-28	AMRN	0.00	0.32	2.46
2026-07-29	AMRN	0.00	0.32	2.46
2026-07-30	AMRN	0.00	0.32	2.46
2026-07-31	AMRN	0.00	0.32	2.46
2026-08-03	AMRN	0.00	0.00	2.45
2026-08-04	AMRN	0.00	0.00	2.45
2026-08-05	AMRN	0.00	0.00	2.45
2026-08-06	AMRN	0.00	0.00	2.45
2026-08-07	AMRN	0.00	0.00	2.45
Date	Ticker	Insider Transactions	Institutional Transactions	Float Short

20 items 1 of 1

Last Quarter Act. EPS

-0.07

Avg. EPS Est. Current Quarter

-0.02

Avg. EPS Est. Next Quarter

-0.01

Insider Transactions

Institutional Transactions

Beta

0.77

Average Sales Estimate Current Quarter

Average Sales Estimate Next Quarter

Fair Value

10.74

Quality Score

Growth Score

Sentiment Score

Actual DrawDown %

Max Drawdown 5-Year %

-93.1

Target Price

P/E

Forward P/E

PEG

P/S

1.62

P/B

0.68

P/Free Cash Flow

19.39

EPS

-1.3

Average EPS Est. Cur. Y

-0.07

EPS Next Y. (Est.)

-0.06

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

-14.57

Relative Volume

0.6

Return on Equity vs Sector %

-33.4

Return on Equity vs Industry %

-43.6

EPS 1 7Days Diff

EPS 1 30Days Diff

-0.04

EBIT Estimation

◆ AMRN Healthcare

$14.36

📉

Swing / Pullback

Buy the dip on strong trends

N/A

WEAK

Trend

18/20

Pullback

17/25

Volume

9/15

Valuation

8/20

TP/AR

0/10

Options

7/10

RSI

48.7

Range 1M

40.1%

Sup Dist

1.6%

🚀

Momentum Growth

Ride accelerating trends

N/A

WEAK

Momentum

6/25

Growth

14/30

Estimates

1/20

Inst/Vol

0/15

Options

7/10

EPS Yr

22.2%

EPS NY

14.3%

52W%

16.6%

💎

Long-Term Value

Quality companies, undervalued

N/A

WEAK

🔴 SELL -21.7% upside

Quality

5/30

Valuation

4/30

Growth

15/25

Stability

6/10

LT Trend

4/5

Upside

-21.7%

Quality

MoS

-25%

AMRN — P/E HistoricalBiotechnology

Amarin Corporation plc

Sector: Healthcare

Industry: Drug Manufacturers - General

Employees: 80

Amarin Corporation plc, a pharmaceutical company, engages in the commercialization and development of therapeutics for the treatment of cardiovascular diseases in the United States, Europe, and internationally. It offers VASCEPA, a prescription-only omega-3 fatty acid product, used as an adjunct to diet for reducing triglyceride levels in adult patients with severe hypertriglyceridemia. The company sells its products principally through wholesalers, selected regional wholesalers, and retail and mail order pharmacy providers. It has a collaboration with Mochida Pharmaceutical Co., Ltd. to develop and commercialize drug products and indications based on the active pharmaceutical ingredient in Vascepa, the omega-3 acid, EPA. The company was formerly known as Ethical Holdings plc and changed its name to Amarin Corporation plc in 1999. Amarin Corporation plc was incorporated in 1989 and is headquartered in Dublin, Ireland.

AMRN

Latest News

—

Caricamento notizie per AMRN…

stock quote shares AMRN – Amarin Corp ADR Stock Price stock today

news today AMRN – Amarin Corp ADR stock forecast ,stock prediction 2023 2024 2025

marketwatch AMRN – Amarin Corp ADR yahoo finance google finance

stock history AMRN – Amarin Corp ADR invest stock market

stock prices AMRN premarket after hours

ticker AMRN fair value insiders trading

GRFS – Grifols, S.A.

GRFS — Price & Float Short

—— Fair value ★ EPS beat ★ EPS miss —— Target Price

Float Short %

2.46

Margin Of Safety %

Put/Call OI Ratio

0.81

EPS Next Q Diff

EPS Last/This Y

0.43

EPS This/Next Y

0.32

Price

7.95

Target Price

12.93

Analyst Recom

2.25

Performance Q

Upside

113.4%

Beta

0.67

Ticker: GRFS

19 items of 1

Date	Symbol	Latest	P/C OI	P/C Vol	Total OI
2026-07-13	GRFS	7.19	0.62	5.23	6336
2026-07-14	GRFS	7	0.74	3.19	6989
2026-07-15	GRFS	7.22	0.76	2.18	7117
2026-07-16	GRFS	7.34	0.81	0.74	7569
2026-07-17	GRFS	7.26	0.81	0.19	7726
2026-07-20	GRFS	7.59	0.83	0.19	6878
2026-07-21	GRFS	7.73	0.84	0.15	6796
2026-07-22	GRFS	7.88	0.82	55.33	6921
2026-07-23	GRFS	7.56	0.86	999.99	7085
2026-07-24	GRFS	7.59	0.88	1.83	7139
2026-07-27	GRFS	7.77	0.87	0.01	7147
2026-07-28	GRFS	7.99	0.84	1.18	7301
2026-07-29	GRFS	8.19	0.83	1.60	7371
2026-07-30	GRFS	8.21	0.84	9.17	7387
2026-07-31	GRFS	7.88	0.83	3.00	7361
2026-08-03	GRFS	7.86	0.83	2.00	7363
2026-08-04	GRFS	8.09	0.83	0.19	7364
2026-08-05	GRFS	7.93	0.82	1.08	7449
2026-08-07	GRFS	7.92	0.81	0.50	7593
Date	Symbol	Latest	P/C OI	P/C Vol	Total OI

19 items 1 of 1

20 items of 1

Date	Ticker	Price	Current Quarter Growth Estimate	EBIT Estimation	Average EPS Estimate Current Year
2026-07-13	GRFS	7.18	23.9	-	1.06
2026-07-14	GRFS	7.01	23.9	-	1.06
2026-07-15	GRFS	7.22	23.9	-	1.06
2026-07-16	GRFS	7.34	23.9	-	1.06
2026-07-17	GRFS	7.25	23.9	-	1.06
2026-07-20	GRFS	7.60	23.9	-	1.06
2026-07-21	GRFS	7.75	23.9	-	1.06
2026-07-22	GRFS	7.89	23.9	-	1.06
2026-07-23	GRFS	7.56	23.9	-	1.06
2026-07-24	GRFS	7.58	23.9	-	1.06
2026-07-27	GRFS	7.78	23.9	-	1.06
2026-07-28	GRFS	7.99	23.9	-	1.06
2026-07-29	GRFS	8.13	23.9	-	1.06
2026-07-30	GRFS	8.22	23.9	-	1.06
2026-07-31	GRFS	7.88	-	-	1.06
2026-08-03	GRFS	7.86	-	-	1.06
2026-08-04	GRFS	7.86	-	-	1.06
2026-08-05	GRFS	7.92	-	-	1.11
2026-08-06	GRFS	7.84	-	-	1.11
2026-08-07	GRFS	7.95	-	-	1.11
Date	Ticker	Price	Current Quarter Growth Estimate	EBIT Estimation	Average EPS Estimate Current Year

20 items 1 of 1

2 items of 1

Date	Ticker	Insider Transactions	Institutional Transactions	Float Short
2026-08-06	GRFS	0.00	-3.97	2.46
2026-08-07	GRFS	0.00	-3.97	2.46
Date	Ticker	Insider Transactions	Institutional Transactions	Float Short

2 items 1 of 1

Last Quarter Act. EPS

Avg. EPS Est. Current Quarter

0.29

Avg. EPS Est. Next Quarter

0.44

Insider Transactions

Institutional Transactions

-3.97

Beta

0.67

Average Sales Estimate Current Quarter

1973

Average Sales Estimate Next Quarter

2081

Fair Value

10.05

Quality Score

Growth Score

Sentiment Score

Actual DrawDown %

Max Drawdown 5-Year %

-65.4

Target Price

12.93

P/E

10.25

Forward P/E

6.49

PEG

0.28

P/S

0.24

P/B

0.85

P/Free Cash Flow

2.17

EPS

0.77

Average EPS Est. Cur. Y

1.11

EPS Next Y. (Est.)

1.43

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

6.09

Relative Volume

0.55

Return on Equity vs Sector %

-19.2

Return on Equity vs Industry %

-29.4

EPS 1 7Days Diff

EPS 1 30Days Diff

0.05

EBIT Estimation

◆ GRFS Healthcare

$7.94

📉

Swing / Pullback

Buy the dip on strong trends

WATCH

Trend

14/20

Pullback

8/25

Volume

11/15

Valuation

18/20

TP/AR

3/10

Options

4/10

RSI

56.5

Range 1M

78.8%

Sup Dist

2.1%

🚀

Momentum Growth

Ride accelerating trends

N/A

WEAK

Momentum

8/25

Growth

8/30

Estimates

7/20

Inst/Vol

0/15

Options

7/10

EPS Yr

12.2%

52W%

28.9%

💎

Long-Term Value

Quality companies, undervalued

N/A

WEAK

🟢 BUY +168.6% upside

Quality

6/30

Valuation

26/30

Growth

8/25

Stability

4/10

LT Trend

3/5

Upside

+168.6%

Quality

MoS

26%

GRFS — P/E HistoricalDrug Manufacturers - General

Grifols, S.A.

Sector: Healthcare

Industry: Drug Manufacturers - General

Employees: 25258

Grifols, S.A., together with its subsidiaries, engages in the research, development, production, and marketing of plasma-derived medicines in the United States, Canada, Spain, Europe, and internationally. It operates through four segments: Biopharma, Diagnostic, Bio Supplies, and Others. The company offers various hemoderivatives from human plasma for immunology, infectious diseases, hepatology, intensive care, pulmonology, hematology, and neurology treatment areas; and markets diagnostic testing equipment, reagents, and other equipment, as well as provides transfusion medicine, clinical diagnostics, and testing services. It also offers biological products, including albumin, albumin-derived products, immunoglobulins, thrombin, other proteins, and intermediate plasma products to pharma and biotech companies for biopharma use; and whole blood, blood components, processed plasma, and clinical samples to life-science research and in-vitro diagnostic companies for diagnostic use. In addition, the company provides healthcare solutions for hospitals, such as intravenous solutions to maintain or restore fluids and electrolyte balance in patients; high-tech solutions to automate hospital processes; clinical nutrition to deliver nutrition and medication; and medical devices comprising instrumentation and disposable materials for various hospital services, which include interventional neuroradiology, hemodynamics, urology, anesthesiology and cardiovascular surgery, as well as manufacturing services to third parties and research activities. Further, it is involved in engineering services; packaging, labelling, storage, distribution, manufacturing, and development of pharmaceutical products; import, export, and commercialization activities; travel agency services; reinsurance of insurance policies; support services; law business; and consultation, administration, and financing services. The company was founded in 1909 and is headquartered in Barcelona, Spain.

GRFS

Latest News

—

Caricamento notizie per GRFS…

stock quote shares GRFS – Grifols, S.A. Stock Price stock today

news today GRFS – Grifols, S.A. stock forecast ,stock prediction 2023 2024 2025

marketwatch GRFS – Grifols, S.A. yahoo finance google finance

stock history GRFS – Grifols, S.A. invest stock market

stock prices GRFS premarket after hours

ticker GRFS fair value insiders trading

SNY – Sanofi

SNY — Price & Float Short

—— Fair value ★ EPS beat ★ EPS miss —— Target Price

Float Short %

0.31

Margin Of Safety %

Put/Call OI Ratio

0.95

EPS Next Q Diff

-0.13

EPS Last/This Y

1.24

EPS This/Next Y

0.39

Price

43.49

Target Price

50.6

Analyst Recom

2.29

Performance Q

Upside

N/A

Beta

0.31

Ticker: SNY

19 items of 1

Date	Symbol	Latest	P/C OI	P/C Vol	Total OI
2026-07-13	SNY	44	0.83	0.13	82542
2026-07-14	SNY	43.17	0.82	0.84	82927
2026-07-15	SNY	43.67	0.83	0.24	83271
2026-07-16	SNY	44.2	0.87	1.28	81971
2026-07-17	SNY	44.66	0.87	0.09	82238
2026-07-20	SNY	43.97	1.00	0.75	70061
2026-07-21	SNY	43.76	1.00	1.11	72256
2026-07-22	SNY	43.81	1.01	0.46	72877
2026-07-23	SNY	43.38	0.99	0.64	74762
2026-07-24	SNY	43.36	1.00	0.68	75955
2026-07-27	SNY	44.03	1.00	2.22	76591
2026-07-28	SNY	45.53	1.00	0.11	77134
2026-07-29	SNY	44.88	0.99	1.58	78039
2026-07-30	SNY	42.89	1.04	0.40	85719
2026-07-31	SNY	43.08	0.95	2.91	91413
2026-08-03	SNY	42.95	0.97	0.57	92815
2026-08-04	SNY	42.7	0.97	1.19	93101
2026-08-05	SNY	42.78	0.97	0.04	93408
2026-08-07	SNY	43.5	0.95	0.35	94726
Date	Symbol	Latest	P/C OI	P/C Vol	Total OI

19 items 1 of 1

20 items of 1

Date	Ticker	Price	Current Quarter Growth Estimate	EBIT Estimation	Average EPS Estimate Current Year
2026-07-13	SNY	44.00	25.3	4293.7	4.92
2026-07-14	SNY	43.16	25.3	3921.3	4.79
2026-07-15	SNY	43.67	25.3	4250.3	4.79
2026-07-16	SNY	44.18	25.3	4266.6	4.79
2026-07-17	SNY	44.64	25.3	4281.9	4.79
2026-07-20	SNY	43.97	25.3	4075.6	4.79
2026-07-21	SNY	43.75	25.3	4081.3	4.79
2026-07-22	SNY	43.80	25.3	4113.8	4.79
2026-07-23	SNY	43.37	25.3	4003.2	4.79
2026-07-24	SNY	43.36	25.3	4209.0	4.79
2026-07-27	SNY	44.01	25.3	4405.0	4.79
2026-07-28	SNY	45.52	25.3	4518.7	4.79
2026-07-29	SNY	44.89	25.3	4165.6	4.79
2026-07-30	SNY	42.93	25.3	3655.2	4.79
2026-07-31	SNY	43.08	-5.7	5721.9	4.79
2026-08-03	SNY	42.96	-5.7	4531.7	4.79
2026-08-04	SNY	42.96	-5.7	4531.7	4.79
2026-08-05	SNY	42.78	-8.9	4647.8	4.88
2026-08-06	SNY	42.90	-8.9	4651.2	4.88
2026-08-07	SNY	43.49	-8.9	4739.4	4.93
Date	Ticker	Price	Current Quarter Growth Estimate	EBIT Estimation	Average EPS Estimate Current Year

20 items 1 of 1

19 items of 1

Date	Ticker	Insider Transactions	Institutional Transactions	Float Short
2026-07-13	SNY	0	-2.21	0.28
2026-07-14	SNY	0	-2.21	0.28
2026-07-15	SNY	0	-2.21	0.28
2026-07-16	SNY	0	-2.21	0.28
2026-07-17	SNY	0	-2.21	0.28
2026-07-20	SNY	0	-2.19	0.28
2026-07-21	SNY	0	-2.19	0.28
2026-07-22	SNY	0	-2.19	0.28
2026-07-23	SNY	0	-2.19	0.28
2026-07-24	SNY	0	-2.19	0.28
2026-07-27	SNY	0	-1.20	0.31
2026-07-28	SNY	0	-1.20	0.31
2026-07-29	SNY	0	-1.20	0.31
2026-07-30	SNY	0	-1.20	0.31
2026-07-31	SNY	0	-1.20	0.31
2026-08-03	SNY	0	-1.25	0.31
2026-08-04	SNY	0	-1.25	0.31
2026-08-05	SNY	0	-1.25	0.31
2026-08-06	SNY	0	-1.25	0.31
Date	Ticker	Insider Transactions	Institutional Transactions	Float Short

19 items 1 of 1

Last Quarter Act. EPS

1.21

Avg. EPS Est. Current Quarter

1.54

Avg. EPS Est. Next Quarter

1.08

Insider Transactions

Institutional Transactions

-1.25

Beta

0.31

Average Sales Estimate Current Quarter

13277

Average Sales Estimate Next Quarter

12441

Fair Value

49.9

Quality Score

Growth Score

Sentiment Score

Actual DrawDown %

27.7

Max Drawdown 5-Year %

-33.5

Target Price

50.6

P/E

22.09

Forward P/E

8.17

PEG

1.13

P/S

1.93

P/B

1.32

P/Free Cash Flow

8.54

EPS

1.94

Average EPS Est. Cur. Y

4.93

EPS Next Y. (Est.)

5.33

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

8.78

Relative Volume

1.23

Return on Equity vs Sector %

-21.6

Return on Equity vs Industry %

-31.8

EPS 1 7Days Diff

0.1

EPS 1 30Days Diff

-0.02

EBIT Estimation

4739.4

No data found for SNY

SNY — P/E HistoricalDrug Manufacturers - General

Sanofi

Sector: Healthcare

Industry: Drug Manufacturers - General

Employees: 74846

Sanofi engages in the research, development, manufacture, and marketing of therapeutic solutions. It provides immunology and inflammation, rare diseases neurology, oncology, and other vaccines. It also offers poliomyelitis, pertussis, and haemophilus influenzae type b (Hib) pediatric vaccines; respiratory syncytial virus protection and hexavalent combination vaccines that includes hepatitis A, typhoid, yellow fever, and rabies vaccines. It has a collaboration and license agreement with Exscientia to develop up to 15 novel small-molecule for oncology and immunology; ABL Bio, Inc. to develop ABL301 for treatment of alpha-synucleinopathies; and Innate Pharma SA for cell engager program targeting B7-H3. Further, it has a collaboration agreements with Atomwise to use ATOMNET platform and Insilico Medicine to use Pharma.AI, a medicine's AI platform; Kymera Therapeutics, Inc. to develop and commercialize protein degrader therapies targeting IRAK4 in patients with immune-inflammatory diseases; Nurix Therapeutics, Inc. to develop protein degradation therapies; Denali Therapeutics Inc. to treat systemic inflammatory diseases, such as ulcerative colitis; and Adagene Inc. for development of antibody-based therapies. Additionally, it has a collaboration with Scribe Therapeutics Inc. to develop genome editing technologies; Teva Pharmaceuticals to co-develop and co-commercialize TEV'574, for treatment of ulcerative colitis and Crohn's disease; and co-promotion service agreement with Provention Bio, Inc. for the commercialization of teplizumab. The company was formerly known as Sanofi-Aventis and changed its name to Sanofi in May 2011. Sanofi was incorporated in 1994 and is headquartered in Paris, France.

SNY

Latest News

—

Caricamento notizie per SNY…

stock quote shares SNY – Sanofi Stock Price stock today

news today SNY – Sanofi stock forecast ,stock prediction 2023 2024 2025

marketwatch SNY – Sanofi yahoo finance google finance

stock history SNY – Sanofi invest stock market

stock prices SNY premarket after hours

ticker SNY fair value insiders trading

NVO – Novo Nordisk A/S

NVO — Price & Float Short

—— Fair value ★ EPS beat ★ EPS miss —— Target Price

Float Short %

0.93

Margin Of Safety %

Put/Call OI Ratio

0.65

EPS Next Q Diff

3.84

EPS Last/This Y

15.87

EPS This/Next Y

1.82

Price

47.24

Target Price

49.1

Analyst Recom

2.38

Performance Q

Upside

N/A

Beta

0.75

Ticker: NVO

19 items of 1

Date	Symbol	Latest	P/C OI	P/C Vol	Total OI
2026-07-13	NVO	49.28	0.68	0.85	1358880
2026-07-14	NVO	49.07	0.69	0.57	1368092
2026-07-15	NVO	50.55	0.69	0.25	1378179
2026-07-16	NVO	51.47	0.68	0.47	1399582
2026-07-17	NVO	50.31	0.69	0.94	1420850
2026-07-20	NVO	49.64	0.62	0.38	1252523
2026-07-21	NVO	49.35	0.62	0.66	1274526
2026-07-22	NVO	48.13	0.62	0.55	1286624
2026-07-23	NVO	48.19	0.62	0.61	1298591
2026-07-24	NVO	48.77	0.62	0.65	1307041
2026-07-27	NVO	49.69	0.63	0.53	1286743
2026-07-28	NVO	50.79	0.63	0.40	1300960
2026-07-29	NVO	51.57	0.63	0.76	1315927
2026-07-30	NVO	51.58	0.63	0.72	1338202
2026-07-31	NVO	47.11	0.64	0.54	1369868
2026-08-03	NVO	47.09	0.65	0.53	1346564
2026-08-04	NVO	44.32	0.65	0.73	1387002
2026-08-05	NVO	44.65	0.65	0.46	1477644
2026-08-07	NVO	47.26	0.65	0.36	1507841
Date	Symbol	Latest	P/C OI	P/C Vol	Total OI

19 items 1 of 1

20 items of 1

Date	Ticker	Price	Current Quarter Growth Estimate	EBIT Estimation	Average EPS Estimate Current Year
2026-07-13	NVO	49.28	-13.1	-4654.1	21.61
2026-07-14	NVO	49.08	-13.1	-4846.3	21.61
2026-07-15	NVO	50.55	-13.1	-4192.4	21.61
2026-07-16	NVO	51.46	-13.1	-4477.9	21.61
2026-07-17	NVO	50.31	-15.7	-5033.2	21.86
2026-07-20	NVO	49.65	-15.7	-4954.6	21.86
2026-07-21	NVO	49.37	-15.7	-5009.4	21.86
2026-07-22	NVO	48.19	-15.7	-4989.6	21.86
2026-07-23	NVO	48.19	-15.7	-4748.9	21.86
2026-07-24	NVO	48.78	-16.4	-4563.6	21.77
2026-07-27	NVO	49.67	-16.4	-4252.3	21.77
2026-07-28	NVO	50.96	-16.4	-4110.5	21.77
2026-07-29	NVO	51.59	-16.4	-4982.6	21.77
2026-07-30	NVO	51.59	-16.4	-5122.0	21.77
2026-07-31	NVO	47.12	-16.4	-6299.5	21.77
2026-08-03	NVO	47.09	-16.4	-5001.2	3.35
2026-08-04	NVO	47.09	-16.4	-5001.2	3.35
2026-08-05	NVO	44.49	-16.4	-4289.9	3.40
2026-08-06	NVO	45.97	-16.4	-3771.8	3.40
2026-08-07	NVO	47.24	4.6	-1075.1	19.43
Date	Ticker	Price	Current Quarter Growth Estimate	EBIT Estimation	Average EPS Estimate Current Year

20 items 1 of 1

19 items of 1

Date	Ticker	Insider Transactions	Institutional Transactions	Float Short
2026-07-13	NVO	0	-2.79	0.83
2026-07-14	NVO	0	-2.79	0.83
2026-07-15	NVO	0	-2.79	0.83
2026-07-16	NVO	0	-2.79	0.83
2026-07-17	NVO	0	-2.79	0.83
2026-07-20	NVO	0	-2.77	0.83
2026-07-21	NVO	0	-2.77	0.83
2026-07-22	NVO	0	-2.77	0.83
2026-07-23	NVO	0	-2.77	0.83
2026-07-24	NVO	0	-2.77	0.83
2026-07-27	NVO	0	-3.46	0.93
2026-07-28	NVO	0	-3.46	0.93
2026-07-29	NVO	0	-3.46	0.93
2026-07-30	NVO	0	-3.46	0.93
2026-07-31	NVO	0	-3.46	0.93
2026-08-03	NVO	0	-3.35	0.93
2026-08-04	NVO	0	-3.35	0.93
2026-08-05	NVO	0	-3.35	0.93
2026-08-06	NVO	0	-3.35	0.93
Date	Ticker	Insider Transactions	Institutional Transactions	Float Short

19 items 1 of 1

Last Quarter Act. EPS

0.96

Avg. EPS Est. Current Quarter

4.7

Avg. EPS Est. Next Quarter

4.8

Insider Transactions

Institutional Transactions

-3.35

Beta

0.75

Average Sales Estimate Current Quarter

71946

Average Sales Estimate Next Quarter

75028

Fair Value

48.57

Quality Score

Growth Score

Sentiment Score

Actual DrawDown %

68.1

Max Drawdown 5-Year %

-74.7

Target Price

49.1

P/E

11.23

Forward P/E

13.83

PEG

P/S

P/B

P/Free Cash Flow

13.09

EPS

4.09

Average EPS Est. Cur. Y

19.43

EPS Next Y. (Est.)

21.25

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

35.36

Relative Volume

0.98

Return on Equity vs Sector %

25.3

Return on Equity vs Industry %

15.1

EPS 1 7Days Diff

-2.3

EPS 1 30Days Diff

-2.17

EBIT Estimation

-1075.1

No data found for NVO

NVO — P/E HistoricalDrug Manufacturers - General

Novo Nordisk A/S

Sector: Healthcare

Industry: Drug Manufacturers - General

Employees: 66700

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products. It operates through two segments, Obesity and Diabetes Care, and Rare Disease. The Obesity and Diabetes care segment provides products for diabetes, obesity, cardiovascular, and other emerging therapy areas. The Rare Disease segment offers products in the areas of rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The company also provides NovoPen 6 and NovoPen Echo Plus, smart insulin pens; Dose Check, an insulin dose guidance application; growth hormone pens and injection needles; and Wegovy pill an oral glucagon-like peptide-1 (GLP-1) receptor agonist therapy for weight management. It operates in Europe, Canada, the United States, Japan, Korea, Oceania, Southeast Asia, Mainland China, Hong Kong and Taiwan, Latin America, the Middle East, and Africa. Novo Nordisk A/S was founded in 1923 and is headquartered in Bagsvaerd, Denmark.

NVO

Latest News

—

Caricamento notizie per NVO…

stock quote shares NVO – Novo Nordisk A/S Stock Price stock today

news today NVO – Novo Nordisk A/S stock forecast ,stock prediction 2023 2024 2025

marketwatch NVO – Novo Nordisk A/S yahoo finance google finance

stock history NVO – Novo Nordisk A/S invest stock market

stock prices NVO premarket after hours

ticker NVO fair value insiders trading

OGN – Organon & Co.

OGN — Price & Float Short

—— Fair value ★ EPS beat ★ EPS miss —— Target Price

Float Short %

6.21

Margin Of Safety %

Put/Call OI Ratio

1.02

EPS Next Q Diff

-0.2

EPS Last/This Y

2.9

EPS This/Next Y

0.02

Price

13.61

Target Price

11.5

Analyst Recom

Performance Q

Upside

-25.4%

Beta

1.51

Ticker: OGN

20 items of 1

Date	Symbol	Latest	P/C OI	P/C Vol	Total OI
2026-07-13	OGN	13.51	0.97	0.56	129239
2026-07-14	OGN	13.5	0.98	1.18	128133
2026-07-15	OGN	13.5	0.98	10.00	128111
2026-07-16	OGN	13.5	0.99	0.41	128166
2026-07-17	OGN	13.52	0.98	0.01	128310
2026-07-20	OGN	13.49	1.02	0.09	120684
2026-07-21	OGN	13.52	1.02	0.01	120650
2026-07-22	OGN	13.52	1.02	1.00	120562
2026-07-23	OGN	13.56	1.02	25.00	120561
2026-07-24	OGN	13.52	1.02	999.99	120612
2026-07-27	OGN	13.54	1.02	0.56	120649
2026-07-28	OGN	13.52	1.02	0.00	120746
2026-07-29	OGN	13.55	1.02	0.52	120740
2026-07-30	OGN	13.55	1.02	0.01	120762
2026-07-31	OGN	13.56	1.02	1.67	120990
2026-08-03	OGN	13.56	1.02	0.88	120998
2026-08-04	OGN	13.56	1.02	1.97	121040
2026-08-05	OGN	13.57	1.02	8.57	121202
2026-08-06	OGN	13.54	1.02	1.06	121253
2026-08-07	OGN	13.61	1.02	2.27	121353
Date	Symbol	Latest	P/C OI	P/C Vol	Total OI

20 items 1 of 1

20 items of 1

Date	Ticker	Price	Current Quarter Growth Estimate	EBIT Estimation	Average EPS Estimate Current Year
2026-07-13	OGN	13.50	7.0	-	3.62
2026-07-14	OGN	13.50	7.0	-	3.62
2026-07-15	OGN	13.50	7.0	-	3.62
2026-07-16	OGN	13.51	7.0	-	3.62
2026-07-17	OGN	13.52	7.0	-	3.62
2026-07-20	OGN	13.50	7.0	-	3.62
2026-07-21	OGN	13.51	7.0	-	3.62
2026-07-22	OGN	13.53	7.0	-	3.62
2026-07-23	OGN	13.56	7.0	-	3.62
2026-07-24	OGN	13.52	7.0	-	3.62
2026-07-27	OGN	13.53	7.0	-	3.62
2026-07-28	OGN	13.52	7.0	-	3.62
2026-07-29	OGN	13.55	7.0	-	3.62
2026-07-30	OGN	13.54	7.0	-	3.62
2026-07-31	OGN	13.55	7.0	-	3.62
2026-08-03	OGN	13.56	7.0	-	3.62
2026-08-04	OGN	13.56	7.0	-	3.62
2026-08-05	OGN	13.57	3.7	-	3.62
2026-08-06	OGN	13.54	3.7	-	3.62
2026-08-07	OGN	13.61	3.7	-	3.62
Date	Ticker	Price	Current Quarter Growth Estimate	EBIT Estimation	Average EPS Estimate Current Year

20 items 1 of 1

19 items of 1

Date	Ticker	Insider Transactions	Institutional Transactions	Float Short
2026-07-13	OGN	2.80	-0.13	6.53
2026-07-14	OGN	2.80	-0.13	6.53
2026-07-15	OGN	2.80	-0.13	6.53
2026-07-16	OGN	2.80	-0.13	6.53
2026-07-17	OGN	2.80	-0.13	6.53
2026-07-20	OGN	2.80	-0.63	6.53
2026-07-21	OGN	2.80	-0.63	6.53
2026-07-22	OGN	2.80	-0.63	6.53
2026-07-23	OGN	2.80	-0.63	6.53
2026-07-24	OGN	2.80	-0.63	6.53
2026-07-27	OGN	2.80	-0.46	6.21
2026-07-28	OGN	2.80	-0.46	6.21
2026-07-29	OGN	2.80	-0.46	6.21
2026-07-30	OGN	2.80	-0.46	6.21
2026-07-31	OGN	2.80	-0.46	6.21
2026-08-03	OGN	2.80	0.32	6.21
2026-08-04	OGN	2.80	0.32	6.21
2026-08-06	OGN	1.22	0.32	6.21
2026-08-07	OGN	1.22	0.32	6.21
Date	Ticker	Insider Transactions	Institutional Transactions	Float Short

19 items 1 of 1

Last Quarter Act. EPS

0.85

Avg. EPS Est. Current Quarter

1.05

Avg. EPS Est. Next Quarter

0.66

Insider Transactions

1.22

Institutional Transactions

0.32

Beta

1.51

Average Sales Estimate Current Quarter

1568

Average Sales Estimate Next Quarter

1532

Fair Value

17.9

Quality Score

Growth Score

Sentiment Score

Actual DrawDown %

65.5

Max Drawdown 5-Year %

-82.7

Target Price

11.5

P/E

17.42

Forward P/E

3.61

PEG

0.9

P/S

0.58

P/B

3.55

P/Free Cash Flow

6.3

EPS

0.78

Average EPS Est. Cur. Y

3.62

EPS Next Y. (Est.)

3.64

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

3.41

Relative Volume

1.14

Return on Equity vs Sector %

-6.5

Return on Equity vs Industry %

-16.7

EPS 1 7Days Diff

0.2

EPS 1 30Days Diff

0.18

EBIT Estimation

◆ OGN Healthcare

$13.60

📉

Swing / Pullback

Buy the dip on strong trends

WEAK

Trend

14/20

Pullback

8/25

Volume

4/15

Valuation

10/20

TP/AR

2/10

Options

3/10

RSI

66.4

Range 1M

100%

Sup Dist

0.5%

🚀

Momentum Growth

Ride accelerating trends

N/A

WEAK

Momentum

11/25

Growth

1/30

Estimates

5/20

Inst/Vol

4/15

Options

1/10

EPS Yr

-3.8%

52W%

99.9%

💎

Long-Term Value

Quality companies, undervalued

N/A

WEAK

🟢 BUY +130.4% upside

Quality

12/30

Valuation

28/30

Growth

2/25

Stability

5/10

LT Trend

1/5

Upside

+130.4%

Quality

MoS

32%

OGN — P/E HistoricalDrug Manufacturers - General

Organon & Co.

Sector: Healthcare

Industry: Drug Manufacturers - General

Employees: 10000

Organon & Co. develops and delivers women health solutions through prescription therapies and medical devices in the United States, Europe, Canada, Japan, rest of the Asia Pacific, China, Latin America, the Middle East, Russia, Africa, and internationally. The company's women's health portfolio comprises contraception and fertility brands, such as Nexplanon, a long-acting reversible contraceptive; NuvaRing, a monthly vaginal contraceptive ring; Cerazette, Marvelon, and Mercilon to prevent pregnancy; Follistim AQ, which is used to promote development of ovarian follicles; Elonva, a follicle stimulant; Ganirelix acetate injection, an injectable antagonist; Jada for abnormal postpartum uterine bleeding and hemorrhage; and Xaciato for bacterial vaginosis. Its biosimilars portfolio consists of immunology products, such as Brenzys, Renflexis, and Hadlima; oncology products, including Ontruzant and Aybintio; Bildyos and Bilprevda, a recombinant anti-RANKL human monoclonal antibodies; and Poherdy, a neu receptor antagonist. The company also offers cholesterol-modifying medicines under the Zetia, Ezetrol, Vytorin, Inegy, Atozet, Rosuzet, and Zocor brands; Cozaar and Hyzaar for hypertension; respiratory products to control and prevent asthma symptoms under the Singulair, Dulera, Zenhale, and Asmanex brands, as well as seasonal allergic rhinitis under the Nasonex, Clarinex, and Aerius brands. In addition, it provides dermatology products under the Vtama, Diprosone, and Elocon brand; bone health products under the Fosamax brand; and non-opioid pain management products under the Arcoxia, Diprospan, and Celestone brands, as well as Proscar for symptomatic benign prostatic hyperplasia; and Propecia for male pattern hair loss. The company serves drug wholesalers and retailers, hospitals, clinics, government agencies, health maintenance organizations, pharmacy benefit managers, and other institutions. Organon & Co. was founded in 1923 and is headquartered in Jersey City, New Jersey.

OGN

Latest News

—

Caricamento notizie per OGN…

stock quote shares OGN – Organon & Co. Stock Price stock today

news today OGN – Organon & Co. stock forecast ,stock prediction 2023 2024 2025

marketwatch OGN – Organon & Co. yahoo finance google finance

stock history OGN – Organon & Co. invest stock market

stock prices OGN premarket after hours

ticker OGN fair value insiders trading

HZNP – Horizon Therapeutics Public Limited Company

HZNP — Price & Float Short

—— Fair value ★ EPS beat ★ EPS miss —— Target Price

Float Short %

3.11

Margin Of Safety %

-6

Put/Call OI Ratio

EPS Next Q Diff

0.02

EPS Last/This Y

EPS This/Next Y

0.18

Price

116.3

Target Price

116.5

Analyst Recom

Performance Q

13.24

Upside

N/A

Beta

1.01

Ticker: HZNP

20 items of 1

Date	Symbol	Latest	P/C OI	P/C Vol	Total OI
2026-07-13	HZNP	116.3	N/A	N/A	0
2026-07-14	HZNP	116.3	N/A	N/A	0
2026-07-15	HZNP	116.3	N/A	N/A	0
2026-07-16	HZNP	116.3	N/A	N/A	0
2026-07-17	HZNP	116.3	N/A	N/A	0
2026-07-20	HZNP	116.3	N/A	N/A	0
2026-07-21	HZNP	116.3	N/A	N/A	0
2026-07-22	HZNP	116.3	N/A	N/A	0
2026-07-23	HZNP	116.3	N/A	N/A	0
2026-07-24	HZNP	116.3	N/A	N/A	0
2026-07-27	HZNP	116.3	N/A	N/A	0
2026-07-28	HZNP	116.3	N/A	N/A	0
2026-07-29	HZNP	116.3	N/A	N/A	0
2026-07-30	HZNP	116.3	N/A	N/A	0
2026-07-31	HZNP	116.3	N/A	N/A	0
2026-08-03	HZNP	116.3	N/A	N/A	0
2026-08-04	HZNP	116.3	N/A	N/A	0
2026-08-05	HZNP	116.3	N/A	N/A	0
2026-08-06	HZNP	116.3	N/A	N/A	0
2026-08-07	HZNP	116.3	N/A	N/A	0
Date	Symbol	Latest	P/C OI	P/C Vol	Total OI

20 items 1 of 1

Last Quarter Act. EPS

1.2

Avg. EPS Est. Current Quarter

1.22

Avg. EPS Est. Next Quarter

1.4

Insider Transactions

Institutional Transactions

1.83

Beta

1.01

Average Sales Estimate Current Quarter

954

Average Sales Estimate Next Quarter

1040

Fair Value

109.22

Quality Score

Growth Score

Sentiment Score

Actual DrawDown %

3.5

Max Drawdown 5-Year %

-50.9

Target Price

116.5

P/E

62.16

Forward P/E

18.11

PEG

12.43

P/S

7.31

P/B

5.01

P/Free Cash Flow

27.79

EPS

1.87

Average EPS Est. Cur. Y

4.64

EPS Next Y. (Est.)

5.66

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

12.02

Relative Volume

Return on Equity vs Sector %

-13.1

Return on Equity vs Industry %

-15.4

EPS 1 7Days Diff

EPS 1 30Days Diff

EBIT Estimation

1038.8

No data found for HZNP

HZNP — P/E HistoricalDrug Manufacturers - General

HZNP

Latest News

—

Caricamento notizie per HZNP…

stock quote shares HZNP – Horizon Therapeutics Public Limited Company Stock Price stock today

news today HZNP – Horizon Therapeutics Public Limited Company stock forecast ,stock prediction 2023 2024 2025

marketwatch HZNP – Horizon Therapeutics Public Limited Company yahoo finance google finance

stock history HZNP – Horizon Therapeutics Public Limited Company invest stock market

stock prices HZNP premarket after hours

ticker HZNP fair value insiders trading

No more stocks to show

AMRN – Amarin Corp ADR

Float Short %

Margin Of Safety %

Put/Call OI Ratio

EPS Next Q Diff

EPS Last/This Y

EPS This/Next Y

Price

Target Price

Analyst Recom

Performance Q

Upside

Beta

Ticker: AMRN

Last Quarter Act. EPS​

Avg. EPS Est. Current Quarter

Avg. EPS Est. Next Quarter

Insider Transactions

Institutional Transactions

Beta

Average Sales Estimate Current Quarter

Average Sales Estimate Next Quarter

Fair Value

Quality Score

Growth Score

Sentiment Score

Actual DrawDown %

Max Drawdown 5-Year %

Target Price

P/E

Forward P/E

PEG

P/S

P/B

P/Free Cash Flow

EPS

Average EPS Est. Cur. Y​

EPS Next Y. (Est.)

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

Relative Volume

Return on Equity vs Sector %

Return on Equity vs Industry %

EPS 1 7Days Diff

EPS 1 30Days Diff

EBIT Estimation

Latest News

GRFS – Grifols, S.A.

Float Short %

Margin Of Safety %

Put/Call OI Ratio

EPS Next Q Diff

EPS Last/This Y

EPS This/Next Y

Price

Target Price

Analyst Recom

Performance Q

Upside

Beta

Ticker: GRFS

Last Quarter Act. EPS​

Avg. EPS Est. Current Quarter

Avg. EPS Est. Next Quarter

Insider Transactions

Institutional Transactions

Beta

Average Sales Estimate Current Quarter

Average Sales Estimate Next Quarter

Fair Value

Quality Score

Growth Score

Sentiment Score

Actual DrawDown %

Max Drawdown 5-Year %

Target Price

P/E

Forward P/E

PEG

Last Quarter Act. EPS

Average EPS Est. Cur. Y

Last Quarter Act. EPS

Average EPS Est. Cur. Y

Last Quarter Act. EPS

Average EPS Est. Cur. Y